Published in PLoS One on July 20, 2012
In vivo animal models for studying brain metastasis: value and limitations. Clin Exp Metastasis (2013) 1.52
Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis. Cancer Res (2013) 1.18
A peptide that inhibits function of Myristoylated Alanine-Rich C Kinase Substrate (MARCKS) reduces lung cancer metastasis. Oncogene (2013) 1.01
Phenotype switching in melanoma: implications for progression and therapy. Front Oncol (2015) 1.00
Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin). Cell Cycle (2012) 0.95
Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking? Lab Invest (2013) 0.92
PTK6 activation at the membrane regulates epithelial-mesenchymal transition in prostate cancer. Cancer Res (2013) 0.92
FKBP51 increases the tumour-promoter potential of TGF-beta. Clin Transl Med (2014) 0.88
Triclosan potentiates epithelial-to-mesenchymal transition in anoikis-resistant human lung cancer cells. PLoS One (2014) 0.87
Fibrillin-1, induced by Aurora-A but inhibited by BRCA2, promotes ovarian cancer metastasis. Oncotarget (2015) 0.84
RhoB loss induces Rac1-dependent mesenchymal cell invasion in lung cells through PP2A inhibition. Oncogene (2015) 0.83
TrkC promotes survival and growth of leukemia cells through Akt-mTOR-dependent up-regulation of PLK-1 and Twist-1. Mol Cells (2013) 0.83
Notch4 Signaling Induces a Mesenchymal-Epithelial-like Transition in Melanoma Cells to Suppress Malignant Behaviors. Cancer Res (2016) 0.82
SPARC/osteonectin is involved in metastatic process to the lung during melanoma progression. Virchows Arch (2014) 0.82
Restoration of the anti-proliferative and anti-migratory effects of 1,25-dihydroxyvitamin D by silibinin in vitamin D-resistant colon cancer cells. Cancer Lett (2015) 0.82
Sulforaphane inhibits thyroid cancer cell growth and invasiveness through the reactive oxygen species-dependent pathway. Oncotarget (2015) 0.81
P-cadherin and the journey to cancer metastasis. Mol Cancer (2015) 0.80
Retracted Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and PH domain and leucine-rich repeat phosphatase cross-talk (PHLPP) in cancer cells and in transforming growth factor β-activated stem cells. J Biol Chem (2014) 0.79
PTTG promotes invasion in human breast cancer cell line by upregulating EMMPRIN via FAK/Akt/mTOR signaling. Am J Cancer Res (2016) 0.78
Fisetin, a dietary flavonoid, augments the anti-invasive and anti-metastatic potential of sorafenib in melanoma. Oncotarget (2016) 0.77
Transforming growth factor-Beta and urokinase-type plasminogen activator: dangerous partners in tumorigenesis-implications in skin cancer. ISRN Dermatol (2013) 0.77
miR-203 Functions as a Tumor Suppressor by Inhibiting Epithelial to Mesenchymal Transition in Ovarian Cancer. J Cancer Sci Ther (2016) 0.77
Fluid shear stress induces epithelial-mesenchymal transition (EMT) in Hep-2 cells. Oncotarget (2016) 0.77
Comparative oncogenomics identifies tyrosine kinase FES as a tumor suppressor in melanoma. J Clin Invest (2017) 0.76
SPARC Controls Melanoma Cell Plasticity through Rac1. PLoS One (2015) 0.76
Overexpression of SPARC correlates with poor prognosis in patients with cervical carcinoma and regulates cancer cell epithelial-mesenchymal transition. Oncol Lett (2016) 0.76
Inhibition of Snail Family Transcriptional Repressor 2 (SNAI2) Enhances Multidrug Resistance of Hepatocellular Carcinoma Cells. PLoS One (2016) 0.75
Identifying and targeting determinants of melanoma cellular invasion. Oncotarget (2016) 0.75
Gigantol Inhibits Epithelial to Mesenchymal Process in Human Lung Cancer Cells. Evid Based Complement Alternat Med (2016) 0.75
Aurora kinases: novel therapy targets in cancers. Oncotarget (2017) 0.75
A Novel Nanoprobe for Multimodal Imaging Is Effectively Incorporated into Human Melanoma Metastatic Cell Lines. Int J Mol Sci (2015) 0.75
Cadherin-6 type 2, K-cadherin (CDH6) is regulated by mutant p53 in the fallopian tube but is not expressed in the ovarian surface. Oncotarget (2016) 0.75
Potential therapeutic targets of epithelial-mesenchymal transition in melanoma. Cancer Lett (2017) 0.75
Gambogenic acid induces cell growth inhibition, cell cycle arrest and metastasis inhibition in choroidal melanoma in a dose-dependent manner. Exp Ther Med (2017) 0.75
An autophagy-driven pathway of ATP secretion supports the aggressive phenotype of BRAF(V600E) inhibitor-resistant metastatic melanoma cells. Autophagy (2017) 0.75
Epithelial-mesenchymal transitions in development and disease. Cell (2009) 39.17
Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer (2007) 18.69
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet (2006) 17.19
The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol (2002) 10.59
Melanoma. N Engl J Med (2006) 8.80
The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development (2005) 8.42
The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res (2002) 6.47
The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci (2003) 6.24
The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet (2005) 4.70
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther (2006) 4.57
Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev (2006) 4.24
Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res (2003) 4.03
Slug antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing puma. Cell (2005) 3.73
Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res (2004) 3.64
The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res (2003) 3.58
Comparison of relative mRNA quantification models and the impact of RNA integrity in quantitative real-time RT-PCR. Biotechnol Lett (2006) 3.53
Developmental transcription factor slug is required for effective re-epithelialization by adult keratinocytes. J Cell Physiol (2005) 2.91
Aberrant expression of the transcription factors snail and slug alters the response to genotoxic stress. Mol Cell Biol (2004) 2.80
Expression of Snail protein in tumor-stroma interface. Oncogene (2006) 2.68
Snail and slug play distinct roles during breast carcinoma progression. Clin Cancer Res (2006) 2.57
Slug, a highly conserved zinc finger transcriptional repressor, protects hematopoietic progenitor cells from radiation-induced apoptosis in vivo. Cancer Cell (2002) 2.48
E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol (2000) 2.36
p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nat Cell Biol (2009) 2.35
Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. Cell Signal (2008) 1.81
Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications. PLoS One (2009) 1.80
Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat Med (1997) 1.76
Deletion of the SLUG (SNAI2) gene results in human piebaldism. Am J Med Genet A (2003) 1.72
SLUG (SNAI2) deletions in patients with Waardenburg disease. Hum Mol Genet (2002) 1.64
A prototypic matricellular protein in the tumor microenvironment--where there's SPARC, there's fire. J Cell Biochem (2008) 1.50
Tbx3 represses E-cadherin expression and enhances melanoma invasiveness. Cancer Res (2008) 1.48
Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Metastasis Rev (2005) 1.46
SPARC: a matricellular regulator of tumorigenesis. J Cell Commun Signal (2009) 1.41
Snai1 and Snai2 collaborate on tumor growth and metastasis properties of mouse skin carcinoma cell lines. Oncogene (2008) 1.40
SPARC represses E-cadherin and induces mesenchymal transition during melanoma development. Cancer Res (2006) 1.31
Slug regulates integrin expression and cell proliferation in human epidermal keratinocytes. J Biol Chem (2006) 1.30
The radioresistance biological function of the SCF/kit signaling pathway is mediated by the zinc-finger transcription factor Slug. Oncogene (2003) 1.26
Transcriptional activation of ZEB1 by Slug leads to cooperative regulation of the epithelial-mesenchymal transition-like phenotype in melanoma. J Invest Dermatol (2011) 1.17
Cadherins in neural crest cell development and transformation. J Cell Physiol (2001) 1.13
HGF induces fibronectin matrix synthesis in melanoma cells through MAP kinase-dependent signaling pathway and induction of Egr-1. Oncogene (2005) 1.11
Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC. Cancer Res (2010) 1.06
H-cadherin expression reduces invasion of malignant melanoma. Pigment Cell Melanoma Res (2009) 1.04
Genetic and epigenetic control in neural crest development. Curr Opin Genet Dev (1994) 0.98
Spleen tyrosine kinase functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest. Cancer Res (2009) 0.95
The p53/p21Cip1/ Waf1 pathway mediates the effects of SPARC on melanoma cell cycle progression. Pigment Cell Melanoma Res (2010) 0.95
Secreted protein acidic and rich in cysteine produced by human melanoma cells modulates polymorphonuclear leukocyte recruitment and antitumor cytotoxic capacity. Cancer Res (2005) 0.94
Osteonectin downregulates E-cadherin, induces osteopontin and focal adhesion kinase activity stimulating an invasive melanoma phenotype. Int J Cancer (2007) 0.93
SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival. Oncogene (2011) 0.93
P-cadherin in adhesion and invasion: opposite roles in colon and bladder carcinoma. Int J Cancer (2011) 0.90
Short interfering RNA directed against the SLUG gene increases cell death induction in human melanoma cell lines exposed to cisplatin and fotemustine. Cell Oncol (2007) 0.87
The cadherin switch in melanoma instigated by HGF is mediated through epithelial-mesenchymal transition regulators. Pigment Cell Melanoma Res (2010) 0.87
Malignancy without immortality? Cellular immortalization as a possible late event in melanoma progression. Pigment Cell Melanoma Res (2011) 0.87
Regulatory expression of genes related to metastasis by TGF-beta and activin A in B16 murine melanoma cells. Mol Biol Rep (2009) 0.83
A secreted form of P-cadherin is expressed in malignant melanoma. Exp Cell Res (2005) 0.83
SRC-1 and TIF2 control energy balance between white and brown adipose tissues. Cell (2002) 4.31
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature (2011) 3.53
Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res (2010) 2.60
Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature (2005) 2.44
Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation. J Biol Chem (2003) 2.38
Loss of Tankyrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubism. Cell (2011) 2.34
IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X(L), and survivin. J Invest Dermatol (2007) 2.31
Demonstration of epitope-spreading phenomena in bullous pemphigoid: results of a prospective multicenter study. J Invest Dermatol (2011) 2.27
NF-1Score: a prediction score for internal neurofibromas in neurofibromatosis-1. J Invest Dermatol (2010) 2.25
Fifteen-year quest for microphthalmia-associated transcription factor target genes. Pigment Cell Melanoma Res (2009) 2.01
Autophagy is required for CSF-1-induced macrophagic differentiation and acquisition of phagocytic functions. Blood (2012) 1.77
ITAM-based interaction of ERM proteins with Syk mediates signaling by the leukocyte adhesion receptor PSGL-1. Immunity (2002) 1.73
Upstream stimulating factors: highly versatile stress-responsive transcription factors. Pigment Cell Res (2005) 1.71
Corkscrew hair: a new dermoscopic sign for diagnosis of tinea capitis in black children. Arch Dermatol (2011) 1.71
GLI2-mediated melanoma invasion and metastasis. J Natl Cancer Inst (2010) 1.68
In vitro and in vivo anti-melanoma effects of ciglitazone. J Invest Dermatol (2009) 1.67
Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy. Pigment Cell Melanoma Res (2013) 1.56
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer (2005) 1.55
Transcription factors and nuclear receptors interact with the SWI/SNF complex through the BAF60c subunit. J Biol Chem (2003) 1.52
Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS). Genes Dev (2011) 1.52
Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome. Arch Dermatol (2008) 1.47
BRCA1 is a new MITF target gene. Pigment Cell Melanoma Res (2011) 1.47
Pol32, a subunit of Saccharomyces cerevisiae DNA polymerase delta, suppresses genomic deletions and is involved in the mutagenic bypass pathway. Genetics (2002) 1.43
Hidradenitis suppurativa and zinc: a new therapeutic approach. A pilot study. Dermatology (2007) 1.41
CD9 expression can be used to predict childhood TEL/AML1-positive acute lymphoblastic leukemia: proposal for an accelerated diagnostic flowchart. Leuk Res (2009) 1.40
Lack of efficacy of tacrolimus in the treatment of vitiligo in the absence of UV-B exposure. Arch Dermatol (2006) 1.40
SOX9 is a key player in ultraviolet B-induced melanocyte differentiation and pigmentation. Proc Natl Acad Sci U S A (2007) 1.32
SPARC represses E-cadherin and induces mesenchymal transition during melanoma development. Cancer Res (2006) 1.31
Dual roles of p300 in chromatin assembly and transcriptional activation in cooperation with nucleosome assembly protein 1 in vitro. Mol Cell Biol (2002) 1.31
Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol (2005) 1.30
Integrative genome-wide analysis reveals a robust genomic glioblastoma signature associated with copy number driving changes in gene expression. Genes Chromosomes Cancer (2009) 1.30
Candidate mechanisms for capecitabine-related hand-foot syndrome. Br J Clin Pharmacol (2008) 1.27
Glycogen synthase kinase 3beta is activated by cAMP and plays an active role in the regulation of melanogenesis. J Biol Chem (2002) 1.27
Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner. Mol Cancer Ther (2013) 1.24
The adaptor protein 3BP2 associates with VAV guanine nucleotide exchange factors to regulate NFAT activation by the B-cell antigen receptor. Blood (2004) 1.22
Microphthalmia-associated transcription factor regulates RAB27A gene expression and controls melanosome transport. J Biol Chem (2008) 1.22
Microphthalmia-associated transcription factor controls the DNA damage response and a lineage-specific senescence program in melanomas. Cancer Res (2010) 1.20
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med (2015) 1.20
Microphthalmia associated transcription factor is a target of the phosphatidylinositol-3-kinase pathway. J Invest Dermatol (2003) 1.17
Hypoxia-inducible factor 1{alpha} is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells. J Cell Biol (2005) 1.14
Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy? Exp Dermatol (2011) 1.14
Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells. J Immunol (2005) 1.13
Aryl hydrocarbon receptor- and calcium-dependent induction of the chemokine CCL1 by the environmental contaminant benzo[a]pyrene. J Biol Chem (2006) 1.13
Signaling through ZAP-70 is required for CXCL12-mediated T-cell transendothelial migration. Blood (2002) 1.13
MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency. J Exp Med (2008) 1.13
Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother (2002) 1.12
Vav1 promotes T cell cycle progression by linking TCR/CD28 costimulation to FOXO1 and p27kip1 expression. J Immunol (2006) 1.12
Up-regulation of MET expression by alpha-melanocyte-stimulating hormone and MITF allows hepatocyte growth factor to protect melanocytes and melanoma cells from apoptosis. J Biol Chem (2007) 1.12
Treatment of oral erosive lichen planus with 1% pimecrolimus cream: a double-blind, randomized, prospective trial with measurement of pimecrolimus levels in the blood. Arch Dermatol (2007) 1.12
Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma. J Clin Oncol (2013) 1.11
HGF induces fibronectin matrix synthesis in melanoma cells through MAP kinase-dependent signaling pathway and induction of Egr-1. Oncogene (2005) 1.11
Naturally occurring melanomas in dogs as models for non-UV pathways of human melanomas. Pigment Cell Melanoma Res (2013) 1.11
Propranolol for treatment of ulcerated infantile hemangiomas. J Am Acad Dermatol (2011) 1.10
Alpha-melanocyte-stimulating hormone counteracts the suppressive effect of UVB on Nrf2 and Nrf-dependent gene expression in human skin. Endocrinology (2009) 1.10
Tumor-derived fibronectin is involved in melanoma cell invasion and regulated by V600E B-Raf signaling pathway. J Invest Dermatol (2006) 1.09
Recruitment of the actin-binding protein HIP-55 to the immunological synapse regulates T cell receptor signaling and endocytosis. J Biol Chem (2004) 1.09
Construction of skin equivalents for gene therapy of recessive dystrophic epidermolysis bullosa. Hum Gene Ther (2004) 1.08
Mammalian actin binding protein 1 is essential for endocytosis but not lamellipodia formation: functional analysis by RNA interference. Biochem Biophys Res Commun (2003) 1.07
Microphthalmia-associated transcription factor (MITF) is required but is not sufficient to induce the expression of melanogenic genes. Pigment Cell Res (2003) 1.07
Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness. J Mol Cell Biol (2012) 1.06
Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC. Cancer Res (2010) 1.06
GLI2 and M-MITF transcription factors control exclusive gene expression programs and inversely regulate invasion in human melanoma cells. Pigment Cell Melanoma Res (2011) 1.06
The chaperone protein 14-3-3 interacts with 3BP2/SH3BP2 and regulates its adapter function. J Biol Chem (2002) 1.06
Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors. Mol Cancer Ther (2009) 1.05
Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid. Clin Immunol (2008) 1.05
Proteolytic regulation of Forkhead transcription factor FOXO3a by caspase-3-like proteases. Oncogene (2003) 1.04
Fatty aldehyde dehydrogenase: potential role in oxidative stress protection and regulation of its gene expression by insulin. J Biol Chem (2003) 1.04
Focal adhesion kinase pp125FAK interacts with the large conductance calcium-activated hSlo potassium channel in human osteoblasts: potential role in mechanotransduction. J Bone Miner Res (2003) 1.03
Aurora B is regulated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in melanoma cells. J Biol Chem (2012) 1.03
The cleavage of microphthalmia-associated transcription factor, MITF, by caspases plays an essential role in melanocyte and melanoma cell apoptosis. Genes Dev (2005) 1.02
Biological and mathematical modeling of melanocyte development. Development (2011) 1.02
UV-induced expression of key component of the tanning process, the POMC and MC1R genes, is dependent on the p-38-activated upstream stimulating factor-1 (USF-1). J Biol Chem (2004) 1.02
BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients. Oncotarget (2012) 1.00
Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients. Cancer Immunol Immunother (2002) 1.00
Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation. Haematologica (2013) 1.00
Characterization of the molecular defects in Rab27a, caused by RAB27A missense mutations found in patients with Griscelli syndrome. J Biol Chem (2003) 1.00
A 4-gene signature associated with clinical outcome in high-grade gliomas. Clin Cancer Res (2011) 0.99
CD47 and the 19 kDa interacting protein-3 (BNIP3) in T cell apoptosis. J Biol Chem (2003) 0.99
Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol (2004) 0.99
Combining evidence, biomedical literature and statistical dependence: new insights for functional annotation of gene sets. BMC Bioinformatics (2006) 0.98
Interactions of human Myosin Va isoforms, endogenously expressed in human melanocytes, are tightly regulated by the tail domain. J Invest Dermatol (2003) 0.98